Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

404 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, Shete S, Hsu CY, Desai A, de Lima Lopes G Jr, Grivas P, Painter CA, Peters S, Thompson MA, Bakouny Z, Batist G, Bekaii-Saab T, Bilen MA, Bouganim N, Larroya MB, Castellano D, Del Prete SA, Doroshow DB, Egan PC, Elkrief A, Farmakiotis D, Flora D, Galsky MD, Glover MJ, Griffiths EA, Gulati AP, Gupta S, Hafez N, Halfdanarson TR, Hawley JE, Hsu E, Kasi A, Khaki AR, Lemmon CA, Lewis C, Logan B, Masters T, McKay RR, Mesa RA, Morgans AK, Mulcahy MF, Panagiotou OA, Peddi P, Pennell NA, Reynolds K, Rosen LR, Rosovsky R, Salazar M, Schmidt A, Shah SA, Shaya JA, Steinharter J, Stockerl-Goldstein KE, Subbiah S, Vinh DC, Wehbe FH, Weissmann LB, Wu JT, Wulff-Burchfield E, Xie Z, Yeh A, Yu PP, Zhou AY, Zubiri L, Mishra S, Lyman GH, Rini BI, Warner JL; COVID-19 and Cancer Consortium. Kuderer NM, et al. Among authors: galsky md. Lancet. 2020 Jun 20;395(10241):1907-1918. doi: 10.1016/S0140-6736(20)31187-9. Epub 2020 May 28. Lancet. 2020. PMID: 32473681 Free PMC article.
Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial.
Ross RW, Galsky MD, Febbo P, Barry M, Richie JP, Xie W, Fennessy FM, Bhatt RS, Hayes J, Choueiri TK, Tempany CM, Kantoff PW, Taplin ME, Oh WK. Ross RW, et al. Among authors: galsky md. Cancer. 2012 Oct 1;118(19):4777-84. doi: 10.1002/cncr.27416. Epub 2012 Jan 26. Cancer. 2012. PMID: 22282219 Free PMC article. Clinical Trial.
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.
Sonpavde G, Pond GR, Fougeray R, Choueiri TK, Qu AQ, Vaughn DJ, Niegisch G, Albers P, James ND, Wong YN, Ko YJ, Sridhar SS, Galsky MD, Petrylak DP, Vaishampayan UN, Khan A, Vogelzang NJ, Beer TM, Stadler WM, O'Donnell PH, Sternberg CN, Rosenberg JE, Bellmunt J. Sonpavde G, et al. Among authors: galsky md. Eur Urol. 2013 Apr;63(4):717-23. doi: 10.1016/j.eururo.2012.11.042. Epub 2012 Nov 26. Eur Urol. 2013. PMID: 23206856 Free PMC article.
Metabolic complications with the use of mTOR inhibitors for cancer therapy.
Sivendran S, Agarwal N, Gartrell B, Ying J, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Galsky MD. Sivendran S, et al. Among authors: galsky md. Cancer Treat Rev. 2014 Feb;40(1):190-6. doi: 10.1016/j.ctrv.2013.04.005. Epub 2013 May 16. Cancer Treat Rev. 2014. PMID: 23684373 Free PMC article. Review.
Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer.
Galsky MD, Xie W, Nakabayashi M, Ross RW, Fennessy FM, Tempany CM, Choueiri TK, Khine K, Kantoff PW, Taplin ME, Oh WK. Galsky MD, et al. Prostate Cancer Prostatic Dis. 2013 Sep;16(3):266-70. doi: 10.1038/pcan.2013.15. Epub 2013 May 28. Prostate Cancer Prostatic Dis. 2013. PMID: 23712318 Free PMC article.
404 results